摘要
与结直肠癌等其他消化系统肿瘤相比，虽然肝细胞癌患者的治疗方案也在不断发展和优化，但是其总生存期（0s）并没有得到明显改善。究其原因，早期微血管侵犯和中晚期门静脉癌栓形成是影响肝细胞癌术后预后不佳的最重要因素。本文就肝细胞癌伴门静脉癌栓的最新治疗进展做一综述，以供临床参考。
Seen from the development of the treatment for hepatocellular carcinoma （HCC）, although great progress has been made on the optimization of the treatment, the patients＇ overall survival （OS） has not been greatly improved compared with other tumors of digestive system such as colorectal cancer. That is mainly because of the early microvascular invasion （MIV） and portal vein tumor thrombus （PVTr） which are a- mong the most important reasons for poor prognosis in HCC. Thus we overviewed the recent research findings on the treatment of HCC with PVTT, which might help the clinicians select the optimal therapeutic strategy.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2016年第3期206-210,共5页
Chinese Journal of Hepatobiliary Surgery
基金
国家自然科学基金（81172287）
关键词
肝细胞癌
微血管癌栓
门静脉癌栓
索拉菲尼
Hepatocellular carcinoma
Microvascularinvasion
Portal vein tumor thrombus
Sorafenib
